

>>> Challenges in IRA Maximum Fair Price:

Effectuation Evaluating the Retrospective and Prospective MFP Models

Tyler Novotny Vice President, Market Economics

Caleb Debenham Senior Director, Global Products & Solutions

Megan Law Senior Director, Portfolio Accounts

Whitley Quan Manager, U.S. Public Policy, Government Affairs





Illustrative


Medicare Part D Retrospective

Potential Part D Retrospective Refund Model

Pharmacy continues to buy at market price with backend manufacturer payment

WAC: \$100
MFP (Medicare Negotiated Price): \$60

--- MFP Based Financial Flow
WAC Based Financial Flow
Data






Potential Part D Prospective Discount Model

Pharmacy buys MFP drug at negotiated price for Medicare patients

Illustrative

Medicare Part D
Prospective







THANK YOU!

